Literature DB >> 25016166

Simultaneous determination of metformin and vildagliptin in human plasma by a HILIC-MS/MS method.

Roberto Pontarolo1, Ana Carolina Gimenez2, Thais Martins Guimarães de Francisco2, Rômulo Pereira Ribeiro2, Flávia Lada Degaut Pontes2, João Cleverson Gasparetto2.   

Abstract

The objective of this work was to develop and validate a HILIC-MS/MS method for the simultaneous determination of metformin and vildagliptin in human plasma. Chromatographic separation was achieved using an Atlantis HILIC Silica 150-mm × 2.1-mm, 3-μm particle size column maintained at 40°C. The isocratic mobile phase consisted of 20% water and 80% acetonitrile/water solution 95:5 (v/v), containing both 0.1% formic acid and 3mM ammonium formate. The flow rate was maintained at 400 μL min(-1). Data from validation studies demonstrated that the new method is highly selective, sensitive (limits of detection <1.5 ng mL(-1)) and free of matrix and residual effects. The new method was also precise (RSD<9.0%), accurate (RE<11.2%) and linear (r ≥ 0.99) over the ranges of 5-500 ng mL(-1) for each compound. The developed method was successfully applied to determine metformin and vildagliptin in plasma volunteers who orally received a single dose of metformin (850 mg), vildagliptin (50mg) or drug association (metformin 850 mg+vildagliptin 50mg). The new method can thus also be used as a tool for the clinical monitoring of metformin and vildagliptin.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HILIC; Human plasma; LC–MS/MS; Metformin; Vildagliptin

Mesh:

Substances:

Year:  2014        PMID: 25016166     DOI: 10.1016/j.jchromb.2014.06.023

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  7 in total

1.  Development, validation of liquid chromatography-tandem mass spectrometry method for simultaneous determination of rosuvastatin and metformin in human plasma and its application to a pharmacokinetic study.

Authors:  P Pavan Kumar; T E G K Murthy; M V Basaveswara Rao
Journal:  J Adv Pharm Technol Res       Date:  2015 Jul-Sep

2.  Simultaneous Quantification of Antidiabetic Agents in Human Plasma by a UPLC-QToF-MS Method.

Authors:  Mariana Millan Fachi; Letícia Bonancio Cerqueira; Letícia Paula Leonart; Thais Martins Guimarães de Francisco; Roberto Pontarolo
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

3.  Hydrophilic Interaction Liquid Chromatography-Electrospray Ionization Mass Spectrometry for Therapeutic Drug Monitoring of Metformin and Rosuvastatin in Human Plasma.

Authors:  Nikolaos Antonopoulos; Giorgos Machairas; George Migias; Ariadni Vonaparti; Vasiliki Brakoulia; Constantinos Pistos; Dimitra Gennimata; Irene Panderi
Journal:  Molecules       Date:  2018-06-27       Impact factor: 4.411

4.  Ecological HPLC method for analyzing an antidiabetic drug in real rat plasma samples and studying the effects of concurrently administered fenugreek extract on its pharmacokinetics.

Authors:  Nada S Abdelwahab; Amani Morsi; Yasmine M Ahmed; Hossam M Hassan; Asmaa M AboulMagd
Journal:  RSC Adv       Date:  2021-01-25       Impact factor: 3.361

5.  Physicochemical Properties and Methods of Analysis of Vildagliptin (Review).

Authors:  E B Polyakova; D R Sabirzyanov; N A Prozorova; A V Foteeva
Journal:  Pharm Chem J       Date:  2022-03-30       Impact factor: 1.063

6.  Development and Greenness Assessment of HPLC Method for Studying the Pharmacokinetics of Co-Administered Metformin and Papaya Extract.

Authors:  Mohamed A Abdelgawad; Mohammed Elmowafy; Arafa Musa; Mohammad M Al-Sanea; AbdElAziz A Nayl; Mohammed M Ghoneim; Yasmine M Ahmed; Hossam M Hassan; Asmaa M AboulMagd; Heba F Salem; Nada S Abdelwahab
Journal:  Molecules       Date:  2022-01-07       Impact factor: 4.411

7.  Formulation of Lipid-Based Tableted Spray-Congealed Microparticles for Sustained Release of Vildagliptin: In Vitro and In Vivo Studies.

Authors:  Khaled H Al Zahabi; Hind Ben Tkhayat; Ehab Abu-Basha; Al Sayed Sallam; Husam M Younes
Journal:  Pharmaceutics       Date:  2021-12-15       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.